FOCUS ON ALS CLINICALS AND DRUG DEVELOPMENT
ROCKVILLE, Md., July 30 /PRNewswire-FirstCall/ -- Stem cell company Neuralstem, Inc. (Amex: CUR) announced that Dr. Thomas Hazel will be rejoining the company as Executive Vice President, Research. He will be working with Dr. Karl Johe, Neuralstem's Chairman and Chief Science Officer, to manage the company's upcoming clinical trial for ALS (Amytrophic Lateral Sclerosis, or Lou Gehrig's disease), and complete development of Neuralstem's small molecule neurogenesis compound targeted to treat depression.
Dr. Hazel returns to Neuralstem after a four year stint as Chief Science Officer at Innovative BioSensors, in Maryland. Prior to that, Dr. Hazel worked with Dr. Johe at Neuralstem for four years to develop the company's techniques for isolating and growing human neural stem cells. Before Neuralstem in 1998, Dr. Hazel worked as a Senior Staff Scientist at the National Institute of Health, which he joined after receiving his Ph.D. in Genetics from the University of Illinois.
"Tom has the background to make a substantial contribution the day he arrives," observed Dr. Johe. "I expect this to accelerate our product development cycle."
"Tom's addition to our senior management team will increase its depth, expand the range of partners that we can work with worldwide, and speed up our progress to market," commented Neuralstem CEO, Richard Garr. "This is an important hire for us."
Neuralstem's patented technology enables, for the first time, the
ability to produce neural stem cells o
|SOURCE Neuralstem, Inc.|
Copyright©2008 PR Newswire.
All rights reserved